Effects of Spironolactone About Vascular Inflammation on a Metabolic Syndrome Model

RENNA NF; GARCIA RD; RAMIREZ JM; MIATELLO RM; MIATELLO RM

Current Research in Diabetes & Obesity Journal

Juniper Publisher

Lugar: new yprk; Año: 2018

2476-1435

BACKGROUND: We considering that aldosterone has pro-oxidative, pro-growth and pro-inflammatory effects, and propose used spironolactone (S) to examine your role in the activation of inflammatory cytokines, NF-kB and VCAM-1 to generate a microenvironment that supports cardiovascular remodeling.METHODS: Male WKY and SHR were separated into five groups: Control, FFR: WKY rats receiving a 10% (w/v) fructose solution during all 12 weeks, SHR, FFHR: SHR receiving a 10% (w/v) fructose solution during all 12 weeks and FFHR+S: (50 mg/kg per day for 6 weeks) (n=8 each group). Metabolic variables and systolic blood pressure were measured. The oxidative stress to evaluate. Cardiac and vascular remodeling were evaluated. To assess the cytokine, NF-kB and VCAM-1 immunostaining techniques were used.RESULTS: The FFHR experimental model presents metabolic syndrome criteria, vascular and cardiac remodeling, vascular inflammation due to increased expression of NF-kB, VCAM-1 and pro-atherogenic cytokines. Spironolactone was able to reverse total or partiality of variables studiedCONCLUSIONS: A MR antagonist, improves vascular function by reducing oxidative stress, upregulating antioxidant systems and moduling inflammatory response. These data imply a role for aldosterone in vascular dysfunction and suggest that spironolactone may have vasoprotective effects in diabetes-associated cardiovascular complications.